<DOC>
	<DOCNO>NCT00104845</DOCNO>
	<brief_summary>RATIONALE : Vaccines make DNA may make body build effective immune response kill tumor cell . PURPOSE : This randomized phase I trial study side effect best dose vaccine therapy treat patient stage IIB , stage IIC , stage III , stage IV melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Stage IIB , Stage IIC , Stage III , Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety feasibility vaccination human mouse gp100 DNA patient stage IIB , IIC , III , IV melanoma . - Determine maximum tolerate dose regimen patient . - Compare antibody T-cell response patient treat two different vaccination schedule . Secondary - Assess antitumor response patient treat regimen . OUTLINE : This randomize , crossover , dose-escalation study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive human gp100 DNA vaccine intramuscularly ( IM ) week 1 , 4 , 7 . Patients receive mouse gp100 DNA vaccine IM week 10 , 13 , 16 . - Arm II : Patients receive mouse gp100 DNA vaccine IM week 1 , 4 , 7 . Patients receive human gp100 DNA vaccine IM week 10 , 13 , 16 . In arm , treatment continue absence disease progression unacceptable toxicity . Cohorts 6-9 patient ( least 3 per treatment arm ) receive escalate dos human mouse gp100 DNA vaccine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 9 patient experience dose-limiting toxicity . After completion study treatment , patient follow 3 week annually 15 year . PROJECTED ACCRUAL : Approximately 18-27 patient accrue study within 6-9 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant melanoma Stage IIB , IIC , III , IV disease Patients stage III IV disease free disease surgical resection* eligible Patients free disease surgical resection* must refuse highdose interferon alfa OR experience recurrent disease prior treatment interferon alfa NOTE : *Patients underwent surgical resection must surgery within past year HLAA0201 positive No detectable brain metastasis PATIENT CHARACTERISTICS : Age Any age Performance status Karnofsky 80100 % Life expectancy Not specify Hematopoietic WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10 g/dL No active bleeding Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) Albumin ≥ 3.5 g/dL AST ALT ≤ 2.5 time ULN Lactate dehydrogenase ≤ 2 time ULN No clinical history hepatitis B C Renal Creatinine ≤ 2.0 mg/dL Immunologic No clinical history HIV No clinical history HTLV1 No active infection require antibiotic within past 72 hour No history collagen vascular , rheumatologic , autoimmune disorder No grade 1 fever within past 72 hour Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Weight ≥ 25 kg No serious underlie medical condition would preclude study participation No preexisting uveal choroidal eye disease PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics More 4 week since prior immunotherapy No prior immunization class vaccine contain gp100 , include whole cell , shed antigen , cell lysate vaccine Chemotherapy More 4 week since prior chemotherapy ( 6 week nitrosoureas ) Endocrine therapy No concurrent corticosteroid would preclude study participation Radiotherapy More 4 week since prior radiotherapy No concurrent radiotherapy Surgery See Disease Characteristics Other Recovered prior therapy No concurrent medication would preclude study participation No concurrent investigational agent No concurrent systemic therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>stage II melanoma</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>